2022-02-25
Ursodeoxycholic acid is a cholelithiant commonly used in the gastroenterology department, and also a cholelithiasis dissolving agent, so it can be used in the treatment of gallstones under normal circumstances, on the premise that the gallbladder has normal contraction function.
When it is only used for lytic treatment, the treatment course is as long as 6 to 24 months, and the oral dose is 10 ml per kg body weight per day.In addition, the drug can treat cholestatic liver diseases, such as primary cholestatic cirrhosis.At the same time can also treat bile reflux gastritis, each time 250 mg, once a day, before going to bed oral.
This medicine can promote the secretion of endogenous bile acid and reduce the reabsorption. Antagonize the cytotoxic effect of hydrophobic bile acid and protect liver cell membrane. Dissolution of cholesterol calculus; Ursodeoxycholic acid capsules should not be taken at the same time with drugs such as caleenine (cholestylamine), Caletipol (cholestylamine), aluminum hydroxide and/or aluminum hydroxide magnesium trisilicate, as these drugs can bind to ursodeoxycholic acid in the intestine, thereby impeding absorption and affecting efficacy.
Ursodeoxycholic acid capsules should be taken two hours before or two hours after taking the drug if the above drug must be taken.Ursodeoxycholic acid capsule can increase the absorption of cyclosporin in the intestinal tract. Patients taking cyclosporin should do the monitoring of cyclosporin serum concentration, and adjust the dose of cyclosporin if necessary. In some cases, ursodeoxycholic acid capsule will reduce the absorption of ciprofloxacin.
This drug is weakly acidic, which is absorbed rapidly through passive diffusion after oral administration, and two peaks of blood drug concentration occur at 1 hour and 3 hours respectively.Because only a small amount of drugs enter the systemic circulation, blood drug concentration is very low.The most effective site of absorption is the ileum, which has a moderately alkaline environment. After absorption, it binds to glycine or taurine in the liver and is discharged from the bile into the small intestine to participate in the enterohepatic circulation.
Lithocholic acid (LCA) was converted by bacteria into the same hydrolyzed part of UDCA in the small intestine, while the other was converted by bacteria into Lithocholic acid (LCA), which thus decreased its potential hepatic toxicity. The therapeutic effect of this drug was related to the concentration of the drug in bile, but not plasma concentration. The half-life is 3.5-5.8 days, mainly excreted with feces, with a small amount of renal excretion. It is not clear whether UDCA is excreted in human breast milk, as only a small amount of UDCA appears in serum after oral administration, and therefore very small amounts, even if UDCA can be secreted into milk.